Technosphere insulin: inhaled prandial insulin

Bibliography

• Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
   Google Scholar
• 2014 National diabetes statistics report. [ cited 2015 Aug 16]. Available from http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html
   Google Scholar
• Peyrot M, Rubin RR, Kruger DF, et al. Correlated of insulin injection omission. Diabetes Care. 2010;33:240–245.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care. 2005;28:2543–2545.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care. 2005;28:2673–2679.
   PubMed Web of Science ®Google Scholar
• Selam JL. Inhaled insulin: promises and concerns. J Diabetes Sci Technol. 2008;2:311–315.
   PubMedGoogle Scholar
• Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1:338–344.
   PubMedGoogle Scholar
• Mandal T. Inhaled insulin for diabetes mellitus. Am J Health-Syst Pharm. 2005;62:1359–1364.
   PubMed Web of Science ®Google Scholar
• McMahon GT, Arky RA. Inhaled insulin for diabetes mellitus. N Engl J Med. 2007;356:497–502.
   PubMed Web of Science ®Google Scholar
• AFREZZA [package insert]. Valencia, CA: MannKind Corporation; 2015. [ cited 2015 Aug 16]. Available from: http://products.sanofi.us/afrezza/afrezza.pdf
   Google Scholar
• Potocka E, Cassidy JP, Haworth P, et al. Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. J Diabetes Sci Technol. 2010;4:1164–1173.
   PubMedGoogle Scholar
• Cassidy PL, Amin N, Marino M, et al. Insulin lung deposition and clearance following technosphere insulin inhalation powder administration. Pharm Res. 2011;28:2157–2164.
   PubMed Web of Science ®Google Scholar
• Neumiller JJ. Campbel RK and Wood LD. A review of inhaled technosphere insulin. Ann Pharmacother. 2010;44:1231–1239.
   PubMed Web of Science ®Google Scholar
• Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11:715–720.
   PubMed Web of Science ®Google Scholar
• An inhaled insulin: Afrezza. Med Lett Drugs Ther. 2015;57:34–35.
   PubMed Web of Science ®Google Scholar
• Baughman R, Cassidy J, Levy B, et al. Technosphere insulin (TI) pharmacokinetics unchanged in subjects who smoke (abstract 427-P). Diabetes. 2008;57:A128.
   Google Scholar
• Fountaine R, Milton A, Checchio T, et al. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. Br J Clin Pharmacol. 2008;65(6):864–870.
   PubMed Web of Science ®Google Scholar
• MannKind Corporation. Briefing document: Endocrinologic and Metabolic Drugs Advisory Committee, April 01, 2014. [ cited 2015 Aug 17]. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommittesMeetingMaterial/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390865.pdf
   Google Scholar
• Bode BW, McGill JB, Lorber DL, et al. Inhaled technosphere insulin compared with injected prandial insulin in tpe 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38:2266–2273.
   Web of Science ®Google Scholar

••Pivotal phase III trial in T1DM conducted by the Affinity 1 Study Group.

• Rosenstock J, Franco D, Korpachev V, et al. Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately contolled on oral antidiabetes agents. Diabetes Care. 2015;38:2274–2281.
   Web of Science ®Google Scholar

••Pivotal phase III trial in T2DM conducted by the Affinity 2 Study Group

• Rosenstock J, Bergenstal R, DeFronzo AR, et al. Efficacy and safety of technosphere inhaled insulin compared with technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31:2177–2182.
   PubMed Web of Science ®Google Scholar

•Important phase II trial.

• Tack CJ, Vladimir C, De Galan BE, et al. Randomized forced titration to different doses of Technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2:47–57.
   PubMedGoogle Scholar

•Important phase II trial.

• Kapsner P, Bergenstal RM, Rendell M, et al. Comparative efficacy and safety of technosphere insulin and a rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Diabetologia. 2009;52(Suppl 1):S386.
   Google Scholar

••Abstract from pivotal phase III trial in T1DM

• Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicenter randomized trial. Lancet. 2010;375:2244–2253.
   PubMed Web of Science ®Google Scholar

••Pivotal phase III trial in T2DM

• Raskin P, Heller S, Honka M, et al. Pulmonary function over two years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obesity Metab. 2012;14:163–173.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther. 2010;12:49–55.
   PubMed Web of Science ®Google Scholar
• Peyrot M, Rubin RR. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled Technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol Ther. 2011;13:1201–1206.
   PubMed Web of Science ®Google Scholar
• Ahren B, Holst JJ. The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. Diabetes. 2001;50:1030–1038.
   PubMed Web of Science ®Google Scholar
• Zisser H, Dassau E, Lee JL, et al Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. J Diabetes Sci Technol. 2015;9:564–572.
   PubMedGoogle Scholar

•Intriguing small trial investigating innovative ways to improve diabetes control